fotemustine has been researched along with Emesis in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (25.00) | 18.2507 |
2000's | 3 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Carapella, CM; Carosi, M; Cognetti, F; Fabi, A; Jandolo, B; Maschio, M; Metro, G; Mirri, MA; Pace, A; Russillo, M; Sperduti, I; Telera, S; Vidiri, A | 1 |
Aapro, MS; Beex, LV; Guastalla, JP; Kobierska, A; Namer, M; Rosso, R; Splinter, TE; ten Bokkel Huinink, W; van der Burg, ME; van Wijk, FH; Vergote, I; Vermorken, JB | 1 |
Baio, S; Berille, J; Le Cesne, A; Le Chevalier, T; Rivière, A | 1 |
Ascierto, PA; Cellerino, R; Comella, G; Comella, P; Daponte, A; DeLena, M; Gravina, A; Marini, G; Melucci, MT; Palmieri, G | 1 |
3 trial(s) available for fotemustine and Emesis
Article | Year |
---|---|
Phase II study of fotemustine in patients with advanced ovarian carcinoma. A trial of the EORTC Gynecological Cancer Group.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Middle Aged; Nausea; Nitrosourea Compounds; Organophosphorus Compounds; Ovarian Neoplasms; Vomiting | 2003 |
Cisplatin-fotemustine combination in inoperable non-small cell lung cancer: preliminary report of a French multicentre phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Nitrosourea Compounds; Organophosphorus Compounds; Vomiting | 1994 |
Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Topics: Adult; Aged; Anemia; Antigens, CD; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Dacarbazine; Female; Fever; Follow-Up Studies; Humans; Interferon-alpha; Male; MART-1 Antigen; Melanoma; Melanoma-Specific Antigens; Membrane Glycoproteins; Middle Aged; Monophenol Monooxygenase; Nausea; Neoplasm Proteins; Neural Cell Adhesion Molecules; Neutropenia; Nitrosourea Compounds; Organophosphorus Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2000 |
1 other study(ies) available for fotemustine and Emesis
Article | Year |
---|---|
Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Topics: Adult; Aged; Antineoplastic Agents; DNA Methylation; Dose-Response Relationship, Drug; Follow-Up Studies; Glioma; Humans; Karnofsky Performance Status; Middle Aged; Multivariate Analysis; Nausea; Neoplasm Recurrence, Local; Neutropenia; Nitrosourea Compounds; O(6)-Methylguanine-DNA Methyltransferase; Organophosphorus Compounds; Promoter Regions, Genetic; Retrospective Studies; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2009 |